Skip to main content
See every side of every news story
Published • loading... • Updated

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

Biogen said the 60-milligram dose also improved five of six cognition and function measures and caused mostly mild side effects.

  • On Tuesday, Biogen presented trial data showing its 60-mg experimental drug dose slowed cognitive decline in early Alzheimer's patients by 38% after two years.
  • Current amyloid-targeting drugs like Leqembi and Eli Lilly's Kisunla slow cognitive decline by 25% to 30%, while the experimental drug targets tau proteins developed with Ionis Pharmaceuticals.
  • Biogen's head of clinical development Diana Gallagher said the 60-mg dose is easier to tolerate than 115-mg regimens, with patients showing improvements in five of six cognition and function measures.
  • The improvement corresponds to a more than 1-point gain on the Clinical Dementia Rating-Sum of Boxes, which Gallagher called "highly clinically meaningful," with no reports of dangerous brain swelling.
  • Biogen is discussing Phase 3 trial outlines with regulators, though results for the experimental drug remain several years away, according to Gallagher.
Insights by Ground AI

16 Articles

ReutersReuters
+2 Reposted by 2 other sources
Center

Biogen's anti-tau Alzheimer's drug benefits increase at 2 years

·London, United Kingdom
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 40% of the sources lean Left, 40% of the sources are Center
40% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Tuesday, November 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal